Previous research has demonstrated that NLRP3-related signalling pathway is a key link in the neuroinflammatory response, and inhibition of NLRP3 can enhance the behaviour and pathological damage of AD in transgenic mice, making it a potential therapeutic target for AD [7–9]. Here, NLRP3 is linked to Alzheimer disease.